Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raf-265. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 17/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 5/20 | 1.00 |
| ▸ | RAF1 | P04049 | 7/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | FYN | P06241 | 3/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 3/20 | 1.00 |
| ▸ | FLT1 | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 | P35916 | 3/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | PAK3 | O75914 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raf-265 SCHEMBL1562237 | 1.00 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL686452 | 1.00 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL29355586 | 1.00 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL1562780 | 0.95 | BRAF (0.91) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL1435408 | 0.95 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL19661215 | 0.95 | BRAF (0.91) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL9976647 | 0.95 | BRAF (0.90) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL1561942 | 0.94 | BRAF (0.88) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL11996499 | 0.93 | BRAF (0.87) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL681128 | 0.93 | BRAF (0.87) | BRAFRAF1KDRLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786750-B2 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | EA PHARMA CO LTD (JP) | 2023-06-28 | — | — | EP | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4665720-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4611901-A1 | RET-LDD PROTEIN DEGRADERS | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4611900-A1 | RET-LDD PROTEIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025129116-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-114502590-A | ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies | 诺华股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114272371-A | Combination therapy comprising anti-PD-1 antibody molecules | 诺华股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022033492-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | BRAF 3140/4885KDR 1464/4885RAF1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.